FDA Lotronex Letter Cites Desire To Work With Glaxo To Maintain Therapy
FDA is willing to continue working with Glaxo Wellcome on a risk management program for Lotronex, the agency said in a Dec. 18 letter to consumers.
FDA is willing to continue working with Glaxo Wellcome on a risk management program for Lotronex, the agency said in a Dec. 18 letter to consumers.